Continuous glucose monitoring system is a device inserted on skin which is a boon for the diabetes patients as it helps to monitor real time Glucose levels in interstitial fluids of the patients. It helps in giving continuous information about the glucose levels and suggesting or maintaining the glucose level in patients. Increasing prevalence of diabetes and advancements in self blood Glucose Monitoring Systems are accelerating the growth of the global continuous glucose monitoring systems market.

The various components included in these systems are: sensors, that detects the level of interstitial glucose; transmitters, that send real time information in the form of readings to the receiver; and integrated insulin pumps, that deliver the required amount of glucose to patient’s body. Among these components, sensors is expected to be the leading category in the continuous glucose monitoring systems market, since these need to be replaced frequently.

North America has the highest prevalence rate for diabetes, due to which the region will hold the largest share in the continuous blood glucose monitoring systems market, throughout the period of analysis. Furthermore, the region had 9.4% of its population having with diabetes, in 2015. Besides, region-wise diabetes prevalence rates are highest in the WHO Eastern Mediterranean followed by South-East Asia, and African Regions, and much lower in the remaining regions. In the European and South-East Asia Regions and the Region of the Americas, high blood glucose mortality rates are considerably higher for men than for women. Such demographic changes are predicted to lead to high demand for these products in the coming years, across the globe.

Dexcom Inc. and Medtronic plc are the two major players in the continuous blood glucose monitoring system industry. Dexcom G4 Platinum, manufactured by Dexcom Inc. has an in built sensor which alerts the users about the rise in glucose level above threshold. Medtronic plc on the other hand markets three products namely: Guardian Real Time, MiniMed Paradigm Real-Time Revel, and MiniMed 530G with Enlite. Among these Guardian Real Time and MiniMed Paradigm Real-Time Revel are approved for pediatric use as well.

The industry is also witnessing several advanced product approvals. For instance, in 2018, the United States Food and Drug Administration (USFDA) approved Guardian Connect System by Medtronic plc, which monitors blood glucose levels in every five minutes and displays the values through the Guardian Connect app installed on a compatible mobile device (i.e., an iPhone or iPad).

Some of the other players in continuous glucose monitoring system industry are: Baxter International Inc., Animas Corporation, Abbott Laboratories, Pfizer Inc., Novo Nordisk, Ypsomed Holding, and GlySens Incorporated.